Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (DE:ISI)
FRANKFURT:ISI
RESEARCH TOOLSreports
Holding DE:ISI?
Track your performance easily
ISI Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€33.38 - €49.00
Previous Close€36.36
Volume0.00
Average Volume (3M)135.00
Market Cap
€5.80B
Enterprise Value€4.12B
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$210.86M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Oct 31, 2024EPS Estimate
-€1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding146,211,091
10 Day Avg. Volume62
30 Day Avg. Volume135
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)20.20
Price to Sales (P/S)7.37
Price to Cash Flow (P/CF)-12.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.07
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda-14.97
Forecast
1Y Price Target
€55.24Price Target Upside51.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue of $225mm beat consensus estimates, primarily driven by R&D revenue.
PartnershipsThe AZN/IONS partnership could mean combo studies where sudden cardiac improvements are expected.
Pipeline And ApprovalsLate-stage pipeline appears very promising, with key approvals expected that can capture significant market share.
Bears Say
Clinical TrialsIONS announced discontinuation of IONIS-FB-LRx for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) as both assets demonstrated insufficient efficacy to advance into Phase 3.
Financial PerformanceUpdating the model for the offering reduces the price target from $62 to $56.
Pipeline ManagementIONS has advanced too many promising drugs that inevitably reduce focus, consume resources, and increase ambiguity around the size/fate of each opportunity.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.75% Insiders
37.17% Mutual Funds
48.11% Other Institutional Investors
11.96% Public Companies and
Individual Investors
ISI FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was €33.38 and its highest was €49.00 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 35 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -€0.405 earnings per share for the quarter, beating the consensus estimate of -€0.833 by €0.428.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -€1.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 157,711,090 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -€0.405 in its last earnings report, beating expectations of -€0.833. Following the earnings report the stock price went down -0.742%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 165M.
---
Ionis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€55.24 (51.91% Upside)
€55.24 (51.91% Upside)
Blogger Sentiment
Bullish
DE:ISI Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.91%
12-Months-Change
Fundamentals
Return on Equity
-105.63%
Trailing 12-Months
Asset Growth
-9.42%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
ISI Company Deck
---
ISI Earnings Call
Q2 2024
0:00 / 0:00
---
ISI Revenue Breakdown
60.82% R&D
39.18% Commercial
---
ISI Stock 12 Month Forecast
Average Price Target
€55.24
▲(51.91% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
AnaptysBio
―
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Voyager Therapeutics
―
Best Analysts Covering ISI
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+16.67%
initiated a buy rating 12 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +16.67% per trade.
---